Brief post-stressor treatment with pregabalin in an animal model for PTSD: Short-term anxiolytic effects without long-term anxiogenic effect

European Neuropsychopharmacology

Volumn 18, Issue 9, 2008, Pages 653-666

  Zohar, Joseph ^a   Matar, Michael A ^b   Ifergane, Gal ^c   Kaplan, Zeev ^b   Cohen, Hagit ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b MENTAL HEALTH CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Animal model; Early drug intervention; Extreme behavioral response; Minimal behavioral response; Post traumatic Stress Disorder; Pregabalin; Secondary prevention

Indexed keywords

PREGABALIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SCREENING; MALE; MAZE TEST; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STARTLE REFLEX; TRANQUILIZING ACTIVITY;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; ANXIETY; AUTOMATIC DATA PROCESSING; BEHAVIOR, ANIMAL; CUES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; MALE; MAZE LEARNING; RATS; RATS, SPRAGUE-DAWLEY; REFLEX, ACOUSTIC; STRESS DISORDERS, POST-TRAUMATIC; TIME FACTORS;

EID: 48749123820     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.04.009     Document Type: Article

References (47)

1. Asnis G.M., Kohn S.R., Henderson M., and Brown N.L. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs 64 (2004) 383-404
2. Bremner J.D., Mletzko T., Welter S., Quinn S., Williams C., Brummer M., et al. Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study. J. Psychopharmacol. 19 (2005) 159-165
3. Cohen H., and Zohar J. Animal models of post traumatic stress disorder: the use of cut off behavioral criteria. Ann. N.Y. Acad. Sci. 1032 (2004) 167-178
4. Cohen H., Joseph Z., and Matar M. The relevance of differential response to trauma in an animal model of post-traumatic stress disorder. Biol. Psychiatry 53 (2003) 463-473
5. Cohen H., Zohar J., Matar M.A., Zeev K., Loewenthal U., and Richter-Levin G. Setting apart the affected: the use of behavioral criteria in animal models of post traumatic stress disorder. Neuropsychopharmacology 29 (2004) 1962-1970
6. Cohen H., Zohar J., Matar M.A., Kaplan Z., and Geva A.B. Unsupervised fuzzy clustering analysis supports behavioral cutoff criteria in an animal model of posttraumatic stress disorder. Biol. Psychiatry 58 (2005) 640-650
7. Cohen H., Kaplan Z., Matar M., Loewenthal U., Kozlovsky N., and Zohar J. Anisomycin, a protein synthesis inhibitor, disrupts traumatic memory consolidation and attenuates post traumatic stress response in rats. Biol. Psychiatry 60 7 (2006) 767-776
8. Cohen H., Matar M.A., Richter-Levin G., and Zohar J. The contribution of an animal model toward uncovering biological risk factors for PTSD. Ann. N.Y. Acad. Sci. 1071 (2006) 335-350
9. Cohen H., Ziv Y., Cardon M., Kaplan Z., Matar M.A., Gidron Y., et al. Maladaptation to mental stress mitigated by the adaptive immune system via depletion of naturally occurring regulatory CD4+CD25+ cells. J. Neurobiol. 66 (2006) 552-563
10. Cohen H., Kaplan Z., Matar M.A., Loewenthal U., Zohar J., and Richter-Levin G. Long-lasting behavioral effects of juvenile trauma in an animal model of PTSD associated with a failure of the autonomic nervous system to recover. Eur. Neuropsychopharmacol. 17 (2007) 464-677
11. Cohen H., Maayan R., Touati-Werner D., Kaplan Z., Matar M., Loewenthal U., et al. Decreased circulatory levels of neuroactive steroids in behaviorally more extremely affected rats subsequent to exposure to a potentially traumatic experience. Int. J. Neuropsychopharmacol. 10 (2007) 203-209
12. Cohen H., Zohar J., Gidron Y., Matar M.A., Belkind D., Loewenthal U., et al. Blunted HPA axis response to stress influences susceptibility to posttraumatic stress response in rats. Biol. Psychiatry 59 (2006) 1208-1218
13. Cohen H., Geva A.B., Matar M.A., Zohar J., and Kaplan Z. Post-traumatic stress behavioural responses in inbred mouse strains: can genetic predisposition explain phenotypic vulnerability?. Int. J. Neuropsychopharmacol. 11 (2008) 331-349
14. Connor K.M., Davidson J.R., Weisler R.H., Zhang W., and Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 184 (2006) 21-25
15. Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52 (2005) 1264-1273
16. Davidson J.R. Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. J. Clin. Psychiatry 65 (2004) 29-33
17. Davidson J.R., Payne V.M., Connor K.M., Foa E.B., Rothbaum B.O., Hertzberg M.A., and Weisler R.H. Trauma, resilience and saliostasis: effects of treatment in post-traumatic stress disorder. Int. Clin. Psychopharmacol. 20 (2005) 43-48
18. Davidson J.R., Brady K., Mellman T.A., Stein M.B., and Pollack M.H. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J. Clin. Psychopharmacol. 27 (2007) 85-88
19. Dworkin R.H., Corbin A.E., Young Jr. J.P., Sharma U., LaMoreaux L., Bockbrader H., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60 (2003) 1274-1283
20. Evenden J., Duncan B., and Ko T. A comparison of the effects of psychotomimetics and anxiolytics on punished and unpunished responding maintained by fixed interval schedules of food reinforcement in the rat. Behav. Pharmacol. 17 (2006) 87-99
21. Feltner D.E., Crockatt J.G., Dubovsky S.J., Cohn C.K., Shrivastava R.K., Targum S.D., et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 23 (2003) 240-249
22. Field M.J., Oles R.J., and Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br. J. Pharmacol. 132 (2001) 1-4
23. Gelpin E., Bonne O., Peri T., Brandes D., and Shalev A.Y. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J. Clin. Psychiatry 57 (1996) 390-394
24. Hertzberg M.A., Butterfield M.I., Feldman M.E., Beckham J.C., Sutherland S.M., Connor K.M., and Davidson J.R. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol. Psychiatry 45 (1999) 1226-1229
25. Kavoussi R. Pregabalin: from molecule to medicine. Eur. Neuropsychopharmacol. 16 Suppl 2 (2006) S128-S133
26. Khan S., and Liberzon I. Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD. Psychopharmacology 172 (2004) 225-229
27. Kim J.J., and Fanselow M.S. Modality-specific retrograde amnesia of fear. Science 256 (1992) 675-677
28. Li S., Murakami Y., Wang M., Maeda K., and Matsumoto K. The effects of chronic valproate and diazepam in a mouse model of posttraumatic stress disorder. Pharmacol. Biochem. Behav. 85 (2006) 324-331
29. Matar M.A., Cohen H., Kaplan Z., and Zohar J. The effect of early poststressor intervention with sertraline on behavioral responses in an animal model of post-traumatic stress disorder. Neuropsychopharmacology 31 (2006) 2610-2618
30. Matar, M., Zohar, J., Kaplan, Z., Cohen, H., submitted for publication. Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD.
31. Mazor, A., Matar, M.A., Kaplan, Z., Kozlovsky, N., Zohar, J., Cohen, H., in press. Gender-related qualitative differences in baseline and post stress anxiety responses are not reflected in the incidence of criterion-based PTSD-like behavior patterns. World J. Biol. Psychiatry 1-14
32. Mula M., Pini S., and Cassano G.B. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol. 27 (2007) 263-272
33. Nicolas L.B., Klein S., and Prinssen E.P. Defensive-like behaviors induced by ultrasound: further pharmacological characterization in Lister-hooded rats. Psychopharmacology (Berl) 194 (2007) 243-252
34. Pande A.C., Pollack M.H., Crockatt J., Greiner M., Chouinard G., Lydiard R.B., et al. Placebo-controlled study of gabapentin treatment of panic disorder. J. Clin. Psychopharmacol. 20 (2000) 467-471
35. Pande A.C., Crockatt J.G., Feltner D.E., Janney C.A., Smith W.T., Weisler R., et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry 160 (2003) 533-540
36. Pande A.C., Feltner D.E., Jefferson J.W., Davidson J.R., Pollack M., Stein M.B., et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J. Clin. Psychopharmacol. 24 (2004) 141-149
37. Pohl R.B., Feltner D.E., Fieve R.R., and Pande A.C. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol. 25 (2005) 151-158
38. Richter R.W., Portenoy R., Sharma U., Lamoreaux L., Bockbrader H., and Knapp L.E. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain 6 (2005) 253-260
39. Rickels K., Pollack M.H., Feltner D.E., Lydiard R.B., Zimbroff D.L., Bielski R.J., et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry 62 (2005) 1022-1030
40. Rosenstock J., Tuchman M., LaMoreaux L., and Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110 (2004) 628-638
41. Sabatowski R., Galvez R., Cherry D.A., Jacquot F., Vincent E., Maisonobe P., and Versavel M. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109 (2004) 26-35
42. Sansone R.A., Hruschka J., Vasudevan A., and Miller S.N. Benzodiazepine exposure and history of trauma. Psychosomatics 44 (2003) 523-524
43. Siddall P.J., Cousins M.J., Otte A., Griesing T., Chambers R., and Murphy T.K. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 67 (2006) 1792-1800
44. Singh L., Field M.J., Ferris P., Hunter J.C., Oles R.J., Williams R.G., and Woodruff G.N. The antiepileptic agent gabapentin (Neurontin (possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl) 127 (1996) 1-9
45. Taylor C.P., Vartanian M.G., Yuen P.W., Bigge C., Suman-Chauhan N., and Hill D.R. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 14 (1993) 11-15
46. Tucker P., Trautman R.P., Wyatt D.B., Thompson J., Wu S.C., Capece J.A., and Rosenthal N.R. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68 (2007) 201-206
47. Yehuda R. Risk and resilience in posttraumatic stress disorder. J. Clin. Psychiatry 65 (2004) 29-36